Fig. 4From: Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scansDistributions of the effective (a) and biological (b) half-lives of 188Re-HDD-Lipiodol in the tumor, liver, lungs, stomach, spleen, and kidneys. The horizontal dashed-line (sub-A) indicates the physical half-life of 188Re (i.e., 17Â h)Back to article page